Fresh triggers kick in for Natco, market share gains for copaxone drug

Natco Pharma remains as one of the few Indian pharma companies to have medium-term revenue visibility

Natco Pharma, which had fallen sharply by 20 per cent in the past one month, and is currently trading near its 52-week lows, surged over six per cent on Monday. These gains follow a favourable judgment by a US court with respect to copaxone drug, and is among the last few patent infringement cases Natco's partner Mylan is defending. With this, and a good show expected in the second half of 2018-19, there could be more gains ahead for Natco, which is among top domestic drug makers that also exports to global markets.

The latest news also eases earlier concerns